Artios and Merck KGaA announce global strategic collaboration

  • Three-year strategic research collaboration to discover and develop multiple precision oncology drugs
  • Merck KGaA shall have the right to opt into exclusive development and commercialisation of compounds on up to eight targets
  • Artios to receive US$30 million in upfront and near-term payments, plus double digit option fees and up to US$860 million in total milestones per target

LONDON, 03 December 2020: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, and Merck KGaA, Darmstadt, Germany (“Merck KGaA”), a leading science and technology company, today announced a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH